Skip to main content

David Drewry

Associate Professor

David Drewry, Ph.D.

Associate Professor, Structural Genomics Consortium UNC


(919) 962-5349
120 Mason Farm Road, 1079 GMB, CB# 7356, Chapel Hill, NC, 27599-7356



David Drewry, Ph.D., is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry spent one year as the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy.


  • “An in silico screen and structural analysis identified bacterial kinase inhibitors which act with β-lactams to inhibit mycobacterial growth” Wlodarchak M, Teachout N, Beczkiewicz J, Procknow R, Schaenzer AJ, Satyshur K, Pavelka M, Zuercher W, Drewry DH, Sauer JD, Striker R, Mol. Pharm., 2018, in press
  • “Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells” Foulkes DM, Byrne DP, Yeung W, Shrestha S, Bailey FP, Ferries S, Eyers CE, Keeshan K, Wells C, Drewry DH, Zuercher WJ, Kannan N, Eyers P, Sci. Signal. 2018, 11 (549) pii:eaat7951.
  • “GW779439X and its pyrazolopyridazine derivatives inhibit the serine/threonine kinase Stk1 and act as antibiotic adjuvants against β-lactam-resistant staphylococcus aureus” Schaenzer AL, Wlodarchak N, Drewry DH, Zuercher WJ, Rose, WE, Ferrer CA, Sauer JD, Striker R, ACS Infectious Diseases, 2018, in press
  • “New tools for evaluating protein tyrosine sulphation: tyrosyl protein sulphotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors” Byrne, DP, Li Y, Ngamlert P, Ramakrishnan K, Eyers CE, Wells CI, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA, Biochem J, 2018, 475 (15) 2435-2455.
  • “New tools for carbohydrate sulphation analysis: heparin sulphate 2-O-sulphotransferase (HS2ST) is a target for small molecule protein kinase inhibitors” Byrne, DP, Li Y, Ramakrishnan K, Barsukov IL, Yates EA, Eyers CE, Papy-Garcia D, Chantepie S, Pagadala V, Lu J, Wells CI, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA, Biochem J, 2018, 475 (15) 2417-2433.
  • “Donated chemical probes for open science” Müller S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, Edwards J, Elkins JM, Fischer C, Frye SV, Gollner A, Grimshaw CE, IJzerman A, Hanke T, Hartung IV, Hitchcock S, Howe T, Hughes TV, Laufer S, Li VM, Liras S, Marsden BD, Matsui H, Mathias J, O’Hagan RC, Owen DR, Pande V, Rauh D, Rosenberg SH, Roth BL, Schneider NS, Scholten C, Singh Saikatendu K, Simeonov A, Takizawa M, Tse C, Thompson PR, Treiber DK, Viana AY, Wells CI, Willson TM, Zuercher WJ, Knapp S, Mueller-Fahrnow A, eLIFE, 2018, 7:e34311.
  • “An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in a rodent model” Price DJ, Drewry DH, Schaller LT, Thompson BD, Reid PR, Maloney PR, Liang X, Banker P, Buckholz RG, Selley PK, McDonald OB, Smith JL, Shearer TW, Cox RF, Williams SP, Reid RA, Tacconi S, Faggioni F, Piubelli C, Sartori I, Tessari M, Wang TY, Bioorg Med Chem Lett, 2018, 28, 1958-1963.
  • “1,2,6-Thiadiazinones as novel narrow spectrum calcium/calmodulin-dependent protein kinase 2 (CAMKK2) inhibitors” Asquith CRM, Godoi PH, Couñago RM, Laitinen T, Scott JW, Langendorf, CG, Oakhill JS, Drewry DH, Zuercher WJ, Koutentis PA, Willson TM, Kalogirou AS, Molecules, 2018, 23 (5), pii: E1221
  • “In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases” Wells CI, Kapadia NR, Couñago RM, Drewry DH, Med Chem Commun, 2018, 9, 44-66.

  • “Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement” Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Hartnett JR, Ingold MR, Zimmerman K, Machleidt T, Kirkland TA, Huwiler KG, Ohana RF, Slater M, Otto P, Cong M, Wells CI, Berger BT, Hanke T, Glas C, Ding K, Drewry DH, Huber KVM, Willson TM, Knapp S, Müller S, Meisenheimer PL, Fan F, Wood KV, Robers MB; Cell Chem Biol, 2017, pii: S2451-9456(17)30391-4. doi: 10.1016/j.chembiol.2017.10.010.
  •  “A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA” Schaenzer AJ, Wlodarchak N, Drewry DH, Zuercher WJ, Rose WE, Striker R, Sauer JD; J Biol Chem. 2017 Oct 13;292(41):17037-17045. doi: 10.1074/jbc.M117.808600. Epub 2017 Aug 16. PubMed PMID: 28821610;
  • “Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes” Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME, PLoS One, 2017, Aug 3;12(8):e0177802. doi: 10.1371/journal.pone.017780
  •  “Progress towards a public chemogenomic set for protein kinases and a call for contributions” Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM
  • PLoS One, 2017, Aug 2;12(8):e0181585. doi: 10.1371/journal.pone.0181585. eCollection 2017. PubMed PMID: 28767711

  • “EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen” Scheipl, S.; Barnard, M.; Cottone, L.; Drewry, D.H.; Zuercher, W.J.; Turlais, F.; Ye, H.; Leite, A.P.; Smith, J.A.; Leither, A.; Möller, P.; Brüderlein, S.; Guppy, N.; Amary, F.; Tirabosco, R.; Strauss, S.J.; Pillay, N.; Flanagan, A.M.; J. Pathology 2016, 239, (3), 320-334.
  • “Comprehensive characterization of the Published Kinase Inhibitor Set” Elkins, JM; Fedele, V; Szklarz, M; Abdul Azeez, KR; Salah, E; Mikolajczyk, J; Romanov, S; Sepetov, N; Huang, XP; Roth, BL; Al Haj Ze, A; Fourches, D; Muratov, E; Tropsha, A; Morris, J; Teicher, BA; Kunkel, M; Polley, E; Lackey, KE; Atkinson, FL; Overington, JP; Bamborough, P; Müller ,S; Price, DJ; Willson, TM; Drewry, DH; Knapp, S; Zuercher, WJ; Nature Biotech. 2016, 34, (1), 95-103.
  • “Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromdomain Containing Protein 9 Inhibition”  Theodoulou, N.H.; Bamborough, P.; Bannister, A.J.; Becher, I.; Bit, R.A.; Che, K.H.; Chung, C-W.; Dittmann, A.; Drewes, G.; Drewry, D.H.; Gordon, L.; Grandi, P.; Leveridge, M.; Lindon, M.; Michon, A-M.; Molnar, J.; Robson, S.C.; Tomkinson, N.C.O.; Kouzarides, T.; Prinjha, R.K.; Humphreys, P.G. J. Med. Chem. 2016, 59, (4), 1425-1439.
  • “Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B” Chen, P.; Chaikuad, A.; Bamborough, P.; Bantscheff, M.; Bountra, C.; Chung, C-w.; Fedorov, O.; Grandi, P.; Jung, D.; Lesniak, R.; Lindon, M.; Muller, S.; Philpott, M.; Prinjha, R.; Rogers, C.; Selenski, C.; Tallant, C.; Werner, T.; Willson, T.; Knapp, S.; Drewry, D.H.  J. Med. Chem. 2016, 59, (4), 1410-1424.
  • “Structure-Bioactivity relationship for benzimidazoles thiophene inhibitors of Polo-like kinase 1 (PLK1) a potentialdrug target in Schistosoma mansoni” Long, T; Neitz, RJ; Beasley, R; Kalyanaraman, C;  Suzuki, BM; Jacobson, MP; Dissous, C; McKerrow, JH; Drewry, DH; Zuercher, WJ; Singh, R; Caffrey, CR; PLoS Neg. Trop. Dis. 2016, 10, (1), e0004356.

  • Al-Ali, H.; Lee, D.H.; Nassif, H.; Gautam, P.; Wennerberg, K.; Zuercher, B.; Drewry, D.H.; Lee, J.K.; Lemmon, V.P.; Bixby, J.L. “Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets to Promote Axon Growth” ACS Chemical Biology 2015, 21, 1939-1951.
  • Pena, I.; Pilar Manzano, M.; Cantizani, J.; Kessler, A.; Alonso-Padilla, J.; Bardera, A.I.; Alvarez, E.; Colmenarejo, G.; Cotillo, I.; Roquero, I.; de Dios-Anton, F.; Barroso, V.; Rodriquez, A.; Gray, D.W.; Navarro, M.; Kumar, V.; Sherstnev, A.; Drewry, D.H.; Brown, J.R.; Fiandor, J.M.; Martin, Julio J. “New compound sets identified from high throughput screening against three kinetoplastid parasites: an open resource” Sci. Rep. 2015, 5, 8771.

  • Drewry, D.H.; Willson, T.M.; Zuercher, W.J. “Seeding collaborations to advance kinases science with the GSK Published Kinase Inhibitor Set (PKIS)” Curr. Topics Med. Chem. 2014, 14, 340-342.

  • Dranchak, P.; MacArthur, R.; Guha, R.; Zuercher, W.J.; Drewry, D.H.; Auld, D.S.; Inglese, J. “Profile of the GSK published kinase inhibitor set across ATP-dependent and –independent luciferases: implications for reporter-gene assays” PLoS One, 2013, 8, e57888.
  • Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D.H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N.; Kuster, B.; Lackey, K.E.; Mazzafera, P.; Tomkinson, N.C.; Willson, T.M.; Workman, P.; Zuercher, W.J. “A public-private partnership to unlock the untargeted kinome” Nat. Chem. Biol. 2013, 9, 3-6.
  • Lucet, I.S.; Tobin, A.; Drewry, D.; Wilks, A.F.; Doerig, C. “Plasmodium kinases as targets for new-generation antimalarials” Future Med. Chem. 2013, 4, 2295-2310.

  • Helan, V.; Mills, A.; Drewry, D.; Grant, D. “A Rapid Three-Component MgI2 Mediated Synthesis of 3,3-Pyrrolidinyl Spirooxindoles” J. Org. Chem. 2010, 75, 6693-6695.
  • Drewry, D.H.; Macarron, R. “Enhancements of screening collections to address areas of unmet medical need: an industry perspective” Curr. Opinion in Chem Biol. 2010, 14, 289-298.
  • Adams, N.D.; Adams, J.L.; Burgess, J.L.; Chaudhari, A.M.; Copeland, R.A.; Donatelli, C.A.; Drewry, D.H.; Fisher, K.E.; Hamajima, T.; Hardwicke, MA.; Huffman, W.F.; Koretke-Brown, K.K.; Lai, Z.V.; McDonald, O.B.; Nakamura, H,; Newlander, K.A.; Oleykowski, C.A.; Parrish, C.A.; Patrick, D.R.; Plant, R.; Sarpong, M.A.; Sasake, K.; Schmidt, S.J.; Silva, D.J.; Sutton, D.; Tang, J.; Thompson, C.S.; Tummino. P.J.; Wang, J.C.; Xiang, H.; Yang, J.; Dhanak, D. “Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase” J. Med. Chem. 2010, 53, 3973-4001.

  • Emmitte, K.A.: Andrews, C.W.; Badiang, J.G.; Davis-Ward, R.G.; Dickson, H.D.; Drewry, D.H.; Emerson, H.K.; Epperly, A.H.; Hassler, D.F.; Knick, V.B.; Kuntz, K.W.; Lansing, T.J.; Linn, J.A.; Mook, R.A. Jr.; Nailor, K.E.; Salovich, J.M.; Spehar, G.M.; Cheung, M. “Discovery of thiophene inhibitors of polo-like kinase” Bioorg. Med. Chem. Lett. 2009, 19, 1018-1021.

  • Bamborough, P.; Drewry, D.; Harper, G.; Smith, G.K.; Schneider, K. “Assessment of Chemical Coverage of Kinome Space and its Implications for Kinase Drug Discovery” J. Med. Chem. 2008, 51, 7898-7914.
  • Deanda, F.; Stewart, E.L.; Reno, M.J.; Drewry, D.H. “Kinase-Targeted Library Design through the Application of the PharmPrint Methodology” J. Chem Inf. and Model. 2008, 48, 2395-2403.

  • “Array synthesis of progesterone receptor antagonists: 3-Aryl-1,2-diazepines” Wiethe, Robert W.; Stewart, Eugene L.; Drewry, David H.; Gray, David W.; Mehbob, Abdul; Hoekstra, William J.,  Bioorganic & Medicinal Chemistry Letters,  2006,  16(14),  3777-3779.

  • “High-Throughput Manual Parallel Synthesis Using SynPhase Crowns and Lanterns”,  Samuel W. Gerritz, Mark H. Norman, Lee A. Barger, Judd Berman, Eric C. Bigham, Michael J. Bishop, David H. Drewry, Deanna T. Garrison, Dennis Heyer, Stephen J. Hodson, Jennifer A. Kakel, James A. Linn, Brian E. Marron, Suganthini S. Nanthakumar, Frank J. Navas III, Journal of Combinatorial Chemistry, 2003, 5(2), 110-117.
  • “New synthetic approaches to estrogen receptor modulators: imidazo[1,2-a]pyridines”,  Hari S. Patel, James A. Linn, David H. Drewry, Daniel A. Hillesheim, William J. Zuercher, and William J. Hoekstra, Tetrahedron Letters, 2003, 44, 4077-4080.

  • “2-(Anilinomethyl)imidazolines as alpha-1A Adrenergic Receptor Agonists: 2’-Heteroaryl and 2”-Oxime Ether Series”,  Frank Navas III, Michael J. Bishop, Deanna T. Garrison, Stephen, J. Hodson, Jason D. Speake, Eric C. Bigham, David H. Drewry, David L. Saussy, James H. Liacos, Paul E. Irving, and M. Jeffrey Gobel, Bioorg. and Med. Chem. Letters, 2002, 12, 575-579.
  • “Optimization of Focused Chemical Libraries Using Recursive Partitioning”,  Andrew Rusinko III, S. Stanley Young, David H. Drewry, and Sam W. Gerritz, Combinatorial Chemistry and High Throughput Screening, 2002, 5, 125-133.

  • “2-Amino-4,6-diarylpyrimidines as Novel Ligands for the Estrogen Receptor”,  Brad R. Henke, David H. Drewry, Stacey A. Jones, Eugene L. Stewart, Susan L. Weaver, and Robert W. Wiethe, Biorg. Med. Chem. Lett., 2001, 11, 1939-1942.

“Solid-Phase Synthesis of 2-aminoimidazolinones”, David H. Drewry, Chiara Ghiron, Tetrahedron Letters, 2000, 41, 6989-6992.

  • “Solid Supported Reagents in Organic Synthesis”, David H. Drewry, Diane M. Coe, and Steve Poon, Medicinal Research Reviews, 1999, 19, 97-148.
  • “Approaches to the Design of Combinatorial Libraries”, David H. Drewry and S. Stanley Young, Chemometrics and Intelligent Laboratory Systems, 1999, 48, 1-20.

  • “Discovery of a potent and selective alpha-1A antagonist: utilization of a rapid screening method to obtain pharmacokinetic parameters”, Adkison, Kimberly K.; Halm, Kathy A.; Shaffer, Joel E.; Drewry, David; Sinhababu, Achintya K.; Berman, Judd; Pharm. Biotechnol. 1998, 11(Integration of Pharmaceutical Discovery and Development), 423-443.

  • “Solid-phase Synthesis of Trisubstituted Guanidines”, David H. Drewry, Samuel W. Gerritz, and James A. Linn, Tetrahedron Lett., 1997, 38, 3377.

  • “Rapid Synthesis of Novel Dipeptide Inhibitors of Human Collagenase and Gelatinase Using Solid Phase Chemistry”, Michael A. Foley, Angela S. Hassman, David H. Drewry, David G. Greer, Craig D. Wagner, Paul L. Feldman, Judd Berman, D. Mark Bickett, Gerry M. McGeehan, M. H. Lambert, M. Green, Bioorg. Med. Chem. Lett., 1996, 6, 1905.

  • “Mechanism and Structure Derived Strategies for the Design of Biologically Active Compounds”, Paul A. Bartlett, Bradley P. Morgan, David H. Drewry, Alan P. Kaplan, John E. Hanson, Siegfried H. Reich, Gary T. Shea, Stephen J. Telfer, Scott C. Waterman, New Methods Drug Res., 1995, 4, 1.

  • “Matrix Metalloproteinase Inhibitors Containing a [(Carboxyalkyl)amino] Zinc Ligand Modification of the P1 and P2’ Residues” F. Brown, P. Brown, D. M. Bickett, C. Chambers, H. Davies, D. Deaton, D. H. Drewry, M. Foley, A. McElroy, M. Gregson, G. M. McGeehan, P. L. Myers, D. Norton, J. Salovich, F. J.Schoenen, P. Ward, J. Med. Chem. 1994, 37, 674.
  • “Structure of the Catalytic Domain of Fibroblast Collagenase Complexed with an Inhibitor”, B. Lovejoy, A. Hassell, K. Longley, M. Luther, D. Weigl, G. McGeehan, A.  McElroy, D. H. Drewry, M. H. Lambert, S. R. Jordan, Science, 1994, 263, 375.

  • “Inhibition of Thermolysin by phosphonamidate transition state analogues: measurement of phosphorus-31-nitrogen-15 bond lengths and chemical shifts in two enzyme-inhibitor complexes by solid-state nuclear magnetic resonance” V. Copie, A. C. Kolbert, D. H. Drewry, P. A. Bartlett, T. G. Oas, R. G. Griffin, Biochemistry, 1990, 29, 9176.

“Details of the interaction of phosphorus-containing peptide inhibitors with Thermolysin” P. A. Bartlett, D. H. Drewry, J. E. Hanson, C. K. Marlowe, Peptides: Chemistry and Biology, Proc. Am. Pept. Symp. 10th, 1988, 427, Ed: G.R. Marshall, Publisher: Escom Sci. Pub., Leiden, Neth.

Select Book Chapters

  • Brown, J. R., Drewry, D., Gamo, F.-J. and Garcia-Bustos, J. F. (2013) “Kinase Inhibitors Among Hits from Malaria Cellular Screens”, in Protein Phosphorylation in Parasites Novel Targets for Antiparasitic Intervention (eds C. Doerig, G. Späth and M. Wiese), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. DOI: 10.1002/9783527675401. Chapter 13. ISBN-13: 978-3527332359.

  • Drewry, D.H.; Bamborough, P.; Schneider, K.; Smith, G.K. (2011) “The Kinome and its Impact on Medicinal Chemistry”, in Kinase Drug Discovery (eds R.A. Ward and F. Goldberg), RSC Publishing, DOI:10.1039/9781849733557. Chapter 1. Print ISBN: 978-1-84973-174-4, PDF eISBN: 978-1-84973-355-7.

  • Adams, J.L.; Bamborough, P.; Drewry, D.H.; Shewchuk, L. (2009) “Strategies for Discovering Kinase Drugs”, in Gene Family Targeted Molecular Design (ed K. Lackey). John Wiley & Sons, Inc. Hoboken, NJ, USA, DOI: 10.1002/9780470423936. Chapter 5. ISBN: 978-0-470-41289-3.

  • “Interplay among enzyme mechanism, protein structure, and the design of serine proteases inhibitors”, P. A. Bartlett, N. S. Sampson, S. H. Reich, D. H. Drewry, L. A. Lamden, in Use of X-Ray Crystallography in the Design of Antiviral Agents, Ed: W.G. Laver and G. M. Air, Publisher: Academic Press, Inc., 1990.

Creation of in vivo active chemical probes for CAMKK2 to treat cancer